Holen Sie sich die Stockscreener-App
10.56
2.46%
0.235
Schlusskurs vom Vortag:
$10.33
Offen:
$9.9
24-Stunden-Volumen:
1.26M
Relative Volume:
0.41
Marktkapitalisierung:
$1.42B
Einnahmen:
$24.30M
Nettoeinkommen (Verlust:
$-145.57M
KGV:
-7.9436
EPS:
-1.33
Netto-Cashflow:
$-149.17M
1W Leistung:
+32.30%
1M Leistung:
+41.21%
6M Leistung:
+475.22%
1J Leistung:
+178.53%
1-Tages-Spanne:
$9.90
$10.75
1-Wochen-Bereich:
$7.83
$11.20
52-Wochen-Spanne:
$1.03
$11.20
Tango Therapeutics Inc Stock (TNGX) Company Profile
Firmenname
Tango Therapeutics Inc
Sektor
Branche
Telefon
(857) 320-4900
Adresse
201 BROOKLINE AVENUE, BOSTON
Vergleichen Sie TNGX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
10.57 | 1.39B | 24.30M | -145.57M | -149.17M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
428.77 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
781.97 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
430.86 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
909.32 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
206.78 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-17 | Eingeleitet | Jefferies | Buy |
| 2024-04-04 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-02-12 | Eingeleitet | Piper Sandler | Overweight |
| 2023-12-08 | Eingeleitet | B. Riley Securities | Buy |
| 2022-10-20 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Tango Therapeutics Inc Aktie (TNGX) Neueste Nachrichten
Novavax, UniFirst, and More Stocks See Action From Activist Investors - Barron's
Tango Therapeutics stock hits 52-week high at 9.7 USD By Investing.com - Investing.com Nigeria
Tango Therapeutics: PRMT5 Inhibitor Vopimetostat Approaches Pivotal TestingBuy (TNGX) - Seeking Alpha
Wall Street Analysts See a 46.07% Upside in Tango Therapeutics (TNGX): Can the Stock Really Move This High? - Finviz
Tango Therapeutics launches $100M at-the-market stock offering - MSN
Tango Therapeutics launches new $100 million at-the-market stock offering By Investing.com - Investing.com Nigeria
Tango Therapeutics Inc files for mixed shelf offeringSEC filing - MarketScreener
Tango Therapeutics files prospectus for resale of 1.7 million shares by selling stockholderSEC filing - MarketScreener
Tango Therapeutics launches new $100 million at-the-market stock offering - Investing.com Nigeria
Tango Therapeutics Enters New Sales Agreement with Leerink - TipRanks
[S-3] Tango Therapeutics, Inc. Shelf Registration Statement | TNGX SEC FilingForm S-3 - Stock Titan
[8-K] Tango Therapeutics, Inc. Reports Material Event | TNGX SEC FilingForm 8-K - Stock Titan
Tango Therapeutics initiated with a Peer Perform at Wolfe Research - MSN
Why Tango Therapeutics Inc. stock remains on watchlists2025 Historical Comparison & Reliable Volume Spike Alerts - newser.com
Short interest data insights for Tango Therapeutics Inc.Weekly Trade Review & Accurate Intraday Trade Tips - newser.com
How analysts rate Tango Therapeutics Inc. stock todayWeekly Profit Analysis & Growth Focused Investment Plans - newser.com
TNGX: Pivotal pancreatic cancer study advances, with strong combo data and cash runway into 2028 - TradingView
Will Tango Therapeutics Inc. stock benefit from automationForecast Cut & Short-Term Trading Alerts - newser.com
TNGX: Vopimetostat advances in pivotal and combo studies, with strong efficacy and cash runway into 2028 - TradingView
Long term hold vs stop loss in Tango Therapeutics Inc.July 2025 Analyst Calls & Safe Capital Growth Plans - newser.com
Why Tango Therapeutics Inc. is moving todayPortfolio Return Report & Free Reliable Trade Execution Plans - newser.com
Wolfe Research Initiates Coverage of Tango Therapeutics (TNGX) with Peer Perform Recommendation - Nasdaq
B. Riley Securities Maintains Tango Therapeutics (TNGX) Buy Recommendation - Nasdaq
Wolfe Research Initiates Coverage on Tango Therapeutics (TNGX) | - GuruFocus
Tango Therapeutics price target raised to $14 from $8 at B. Riley - TipRanks
B. Riley Adjusts Price Target on Tango Therapeutics to $14 From $8, Maintains Buy Rating - MarketScreener
Will Tango Therapeutics Inc. stock maintain dividend yieldInsider Selling & Reliable Breakout Forecasts - newser.com
Using AI based signals to follow Tango Therapeutics Inc.2025 Macro Impact & Short-Term High Return Strategies - newser.com
Does Tango Therapeutics Inc. fit your quant trading modelMarket Growth Report & Daily Market Momentum Tracking - newser.com
Can Tango Therapeutics Inc. stock outperform in 2025 bull marketWeekly Profit Report & Advanced Swing Trade Entry Alerts - newser.com
How Tango Therapeutics Inc. stock performs in rising dollar environment2025 Geopolitical Influence & AI Based Buy/Sell Signal Reports - newser.com
Why Tango Therapeutics Inc. stock is trending among retail tradersWeekly Market Outlook & Daily Volume Surge Trade Alerts - newser.com
Will Tango Therapeutics Inc. stock attract ESG investorsMarket Rally & Daily Profit Maximizing Trade Tips - newser.com
Tango Therapeutics’ Promising Update on TNG260 Clinical Study - MSN
Tango Therapeutics (TNGX): Evaluating Valuation Following Strong Revenue Growth and Doubling Share Price - Yahoo Finance
Finanzdaten der Tango Therapeutics Inc-Aktie (TNGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.72%
1.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):